Demant stock holds above DKK290 as analysts lift targets

Demant A/S (ISIN DK0010268440) stock is quoted at DKK294.00 in real-time estimates as of August 17, 2026, with a modest intraday decline of 1.14 percent but a strong year-to-date gain of 36.90 percent.

On August 17, 2026, one analyst overview reports a last close at DKK297.40 and an average target price of DKK290.25, implying that the current quote trades about 2.40 percent above the consensus target level.

For investors, this mix of short-term softness against a backdrop of solid longer-term performance suggests that valuation and expectations now sit in a relatively tight band around the DKK290 mark.

Analyst targets support current valuation

A detailed analyst snapshot dated August 17, 2026, shows Demant quoted at DKK294.00 in real-time Cboe Europe estimates, with a five-day percentage change of negative 1.14 percent.

The same overview highlights a first trading day of the year change of positive 6.35 percent and a year-to-date performance of positive 36.90 percent, underscoring that Demant stock has delivered substantial returns over the course of 2026 even if the latest sessions have been more muted.

With an average target price of DKK290.25 contrasted against the last close at DKK297.40, the data indicates that Demant currently trades slightly above the consensus valuation band, by around 2.40 percent, which may limit upside near term unless new earnings or guidance surprises emerge.

Recent rating changes frame sentiment

Alongside the broader consensus, one broker action summary recorded in mid-July 2026 shows that Demant was downgraded to a more neutral stance with a target price of DKK276.00, up from a previous DKK267.00 level.

This combination of a higher absolute target but a more cautious rating signals that some coverage providers view Demant's strong share price run and double-digit year-to-date gains as largely reflecting the current fundamental outlook.

In contrast, the August 17, 2026, average target of DKK290.25 sits closer to the live price, suggesting that the wider group of analysts is aligned around a valuation corridor slightly below the latest close, while the share's 36.90 percent rise since the start of the year shows why rating language has shifted to a more balanced tone.

Hearing solutions underpin the business

Demant develops and markets hearing aid devices and related audiology equipment, positioning itself as a key player in the global hearing health sector.

The company offers a portfolio that includes digitally programmable hearing aids, diagnostic instruments for audiologists, and accessories designed to improve speech understanding in challenging sound environments.

Across many markets, Demant supports its hearing solutions with fitting software and professional services that help clinics tailor devices to individual users, which in turn drives recurring demand and provides a foundation for the revenue and earnings figures that analysts reference in their target price calculations.

Shares trade on the Copenhagen exchange

Demant shares are listed on the Copenhagen exchange, with the latest available real-time estimate on August 17, 2026, showing a DKK294.00 quote and daily trading within a band between DKK294.00 and the prior close at DKK297.40.

As of the latest session, the intraday decline of 1.14 percent contrasts with the much larger year-to-date rise of 36.90 percent, indicating that most of the share price appreciation has occurred over previous months and that current trading reflects a period of consolidation.

For investors tracking the name, the fact that Demant stock trades a little above the average target of DKK290.25 while still showing a strong performance since January suggests a balance between optimism on the hearing health business and a more measured view on further upside without fresh operational catalysts.

Go deeper

Read the latest Demant stock price context and performance overview.

Investor Relations

More on Demant stock.

Key hearing aid brands and technology

Among Demant's hearing-related offerings, branded hearing aids and professional audiology tools stand out as a representative product segment for retail and clinical customers.

Current market commentary on hearing devices notes that premium models in the sector can reach price points above $2,500 per unit in some regions, reflecting both advanced technology and the value placed on improved hearing outcomes.

Demant participates in this high-value segment by supplying digital hearing aids and associated software that aim to optimize sound processing and user comfort, providing the type of product mix that underpins the company's long-term growth story cited in analyst research.

Demant stock price snapshot

Based on real-time Cboe Europe estimates as of August 17, 2026, at 8:37 a.m. EDT, Demant stock is quoted at DKK294.00, down 1.14 percent on the day compared with the previous close at DKK297.40.

The same data set records that Demant shares are up 6.35 percent since the first trading day of the year and 36.90 percent on a year-to-date basis, providing a clear quantified comparison between short-term fluctuations and the broader upward trend.

This profile of modest daily volatility against a much stronger annual gain means that investors now weigh whether the DKK294.00 level and the DKK290.25 average target price leave room for further appreciation or instead mark a phase of consolidation after a strong run.

Fact box

Company: Demant A/S

ISIN: DK0010268440

Ticker: DEMANT

Exchange: Copenhagen Stock Exchange

Price (as of August 17, 2026, 8:37 a.m. EDT): DKK294.00

Sector / Industry: Health care equipment and supplies

Index membership: Copenhagen large-cap segment